Rationale and design of the ESC Heart Failure III Registry - Implementation and discovery.
Heart failure
Implementation
Phenotyping
Quality of care
Registry
Journal
European journal of heart failure
ISSN: 1879-0844
Titre abrégé: Eur J Heart Fail
Pays: England
ID NLM: 100887595
Informations de publication
Date de publication:
21 Nov 2023
21 Nov 2023
Historique:
revised:
31
10
2023
received:
23
06
2023
accepted:
04
11
2023
pubmed:
22
11
2023
medline:
22
11
2023
entrez:
22
11
2023
Statut:
aheadofprint
Résumé
Heart failure outcomes remain poor despite advances in therapy. The European Society of Cardiology Heart Failure III Registry (ESC HF III Registry) aims to characterize HF clinical features and outcomes and to assess implementation of guideline-recommended therapy in Europe and other ESC affiliated countries. Between 1 November 2018 and 31 December 2020, 10 162 patients with chronic or acute/worsening HF with reduced, mildly reduced, or preserved ejection fraction were enrolled from 220 centres in 41 European or ESC affiliated countries. The ESC HF III Registry collected data on baseline characteristics (hospital or clinic presentation), hospital course, diagnostic and therapeutic decisions in hospital and at the clinic visit; and on outcomes at 12-month follow-up. These data include demographics, medical history, physical examination, biomarkers and imaging, quality of life, treatments, and interventions - including drug doses and reasons for non-use, and cause-specific outcomes. The ESC HF III Registry will provide comprehensive and unique insight into contemporary HF characteristics, treatment implementation, and outcomes, and may impact implementation strategies, clinical discovery, trial design, and public policy.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: A comprehensive and updated review of epidemiology. Cardiovasc Res 2023;118:3272-3287. https://doi.org/10.1093/cvr/cvac013
Becher PM, Lund LH, Coats AJS, Savarese G. An update on global epidemiology in heart failure. Eur Heart J 2022;43:3005-3007. https://doi.org/10.1093/eurheartj/ehac248
Rosano GMC, Seferovic P, Savarese G, Spoletini I, Lopatin Y, Gustafsson F, et al. Impact analysis of heart failure across European countries: An ESC-HFA position paper. ESC Heart Fail 2022;9:2767-2778. https://doi.org/10.1002/ehf2.14076
Johansson I, Joseph P, Balasubramanian K, McMurray JJV, Lund LH, Ezekowitz JA, et al.; G-CHF Investigators. Health-related quality of life and mortality in heart failure: The Global Congestive Heart Failure study of 23 000 patients from 40 countries. Circulation 2021;143:2129-2142. https://doi.org/10.1161/CIRCULATIONAHA.120.050850
Stolfo D, Lund LH, Benson L, Hage C, Sinagra G, Dahlström U, et al. Persistent high burden of heart failure across the ejection fraction spectrum in a nationwide setting. J Am Heart Assoc 2022;11:e026708. https://doi.org/10.1161/JAHA.122.026708
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al.; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2022;24:4-131. https://doi.org/10.1002/ejhf.2333
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2023;2023:3627-3639. https://doi.org/10.1093/eurheartj/ehad195
Sidney S, Go AS, Jaffe MG, Solomon MD, Ambrosy AP, Rana JS. Association between aging of the US population and heart disease mortality from 2011 to 2017. JAMA Cardiol 2019;4:1280-1286. https://doi.org/10.1001/jamacardio.2019.4187
Batra G, Aktaa S, Benson L, Dahlström U, Hage C, Savarese G, et al. Association between heart failure quality of care and mortality: A population-based cohort study using nationwide registries. Eur J Heart Fail 2022;24:2066-2077. https://doi.org/10.1002/ejhf.2725
Lim YMF, Molnar M, Vaartjes I, Savarese G, Eijkemans MJC, Uijl A, et al. Generalizability of randomized controlled trials in heart failure with reduced ejection fraction. Eur Heart J Qual Care Clin Outcomes 2022;8:761-769. https://doi.org/10.1093/ehjqcco/qcab070
Girerd N, von Hunolstein JJ, Pellicori P, Bayés-Genís A, Jaarsma T, Lund LH, et al.; EF-HF Group. Therapeutic inertia in the pharmacological management of heart failure with reduced ejection fraction. ESC Heart Fail 2022;9:2063-2069. https://doi.org/10.1002/ehf2.13929
Savarese G, Carrero JJ, Pitt B, Anker SD, Rosano GMC, Dahlström U, et al. Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: An analysis of 11 215 patients from the Swedish Heart Failure Registry. Eur J Heart Fail 2018;20:1326-1334. https://doi.org/10.1002/ejhf.1182
Savarese G, Vasko P, Jonsson A, Edner M, Dahlström U, Lund LH. The Swedish Heart Failure Registry: A living, ongoing quality assurance and research in heart failure. Ups J Med Sci 2019;124:65-69. https://doi.org/10.1080/03009734.2018.1490831
Savarese G, Stolfo D, Sinagra G, Lund LH. Heart failure with mid-range or mildly reduced ejection fraction. Nat Rev Cardiol 2022;19:100-116. https://doi.org/10.1038/s41569-021-00605-5
Ahmad T, Lund LH, Rao P, Ghosh R, Warier P, Vaccaro B, et al. Machine learning methods improve prognostication, identify clinically distinct phenotypes, and detect heterogeneity in response to therapy in a large cohort of heart failure patients. J Am Heart Assoc 2018;7:e008081. https://doi.org/10.1161/JAHA.117.008081
Uijl A, Savarese G, Vaartjes I, Dahlström U, Brugts JJ, Linssen GCM, et al. Identification of distinct phenotypic clusters in heart failure with preserved ejection fraction. Eur J Heart Fail 2021;23:973-982. https://doi.org/10.1002/ejhf.2169
Butler J, Hamo CE, Udelson JE, O'Connor C, Sabbah HN, Metra M, et al. Reassessing phase II heart failure clinical trials: Consensus recommendations. Circ Heart Fail 2017;10:e003800. https://doi.org/10.1161/CIRCHEARTFAILURE.116.003800
Lund LH, Carrero JJ, Farahmand B, Henriksson KM, Jonsson Å, Jernberg T, et al. Association between enrolment in a heart failure quality registry and subsequent mortality - A nationwide cohort study. Eur J Heart Fail 2017;19:1107-1116. https://doi.org/10.1002/ejhf.762
Cleland JG, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, et al.; Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The EuroHeart Failure Survey programme - A survey on the quality of care among patients with heart failure in Europe. Part 1: Patient characteristics and diagnosis. Eur Heart J 2003;24:442-463. https://doi.org/10.1016/s0195-668x(02)00823-0
Nieminen MS, Brutsaert D, Dickstein K, Drexler H, Follath F, Harjola VP, et al.; EuroHeart Survey Investigators; Heart Failure Association, European Society of Cardiology. EuroHeart Failure Survey II (EHFS II): A survey on hospitalized acute heart failure patients: Description of population. Eur Heart J 2006;27:2725-2736. https://doi.org/10.1093/eurheartj/ehl193
Maggioni AP, Anker SD, Dahlström U, Filippatos G, Ponikowski P, Zannad F, et al.; Heart Failure Association of the ESC (HFA). Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 2013;15:1173-1184. https://doi.org/10.1093/eurjhf/hft134
Kapłon-Cieślicka A, Benson L, Chioncel O, Crespo-Leiro MG, Coats AJS, Anker SD, et al.; Heart Failure Association (HFA) of the European Society of Cardiology (ESC) and the ESC Heart Failure Long-Term Registry Investigators. A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction - Insights from the ESC-HFA EORP Heart Failure Long-Term Registry. Eur J Heart Fail 2022;24:335-350. https://doi.org/10.1002/ejhf.2408
Senni M, Gavazzi A, Oliva F, Mortara A, Urso R, Pozzoli M, et al. In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs. worsening) and ejection fraction. Results from IN-HF Outcome Registry. Int J Cardiol 2014;173:163-169. https://doi.org/10.1016/j.ijcard.2014.02.018
Fonarow GC, Abraham WT, Albert NM, Gattis WA, Gheorghiade M, Greenberg B, et al. Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): Rationale and design. Am Heart J 2004;148:43-51. https://doi.org/10.1016/j.ahj.2004.03.004
Fonarow GC, Albert NM, Curtis AB, Stough WG, Gheorghiade M, Heywood JT, et al. Improving evidence-based care for heart failure in outpatient cardiology practices: Primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF). Circulation 2010;122:585-596. https://doi.org/10.1161/CIRCULATIONAHA.109.934471
Fonarow GC, Yancy CW, Heywood JT. Adherence to heart failure quality-of-care indicators in US hospitals: Analysis of the ADHERE registry. Arch Intern Med 2005;165:1469-1477. https://doi.org/10.1001/archinte.165.13.1469
MacDonald MR, Tay WT, Teng TK, Anand I, Ling LH, Yap J, et al. Regional variation of mortality in heart failure with reduced and preserved ejection fraction across Asia: Outcomes in the ASIAN-HF registry. J Am Heart Assoc 2020;9:e012199. https://doi.org/10.1161/JAHA.119.012199
Cunningham LC, Fonarow GC, Yancy CW, Sheng S, Matsouaka RA, DeVore AD, et al. Regional variations in heart failure quality and outcomes: Get With The Guidelines-Heart Failure Registry. J Am Heart Assoc 2021;10:e018696. https://doi.org/10.1161/JAHA.120.018696
Tromp J, Ouwerkerk W, Teng TK, Cleland JGF, Bamadhaj S, Angermann CE, et al. Global disparities in prescription of guideline-recommended drugs for heart failure with reduced ejection fraction. Eur Heart J 2022;43:2224-2234. https://doi.org/10.1093/eurheartj/ehac103
Komajda M, Cowie MR, Tavazzi L, Ponikowski P, Anker SD, Filippatos GS; QUALIFY Investigators. Physicians' guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: The QUALIFY international registry. Eur J Heart Fail 2017;19:1414-1423. https://doi.org/10.1002/ejhf.887
Linssen GCM, Veenis JF, Brunner-la Rocca HP, van Pol PEJ, Engelen DJM, van Tooren RM, et al.; CHECK-HF Investigators. Differences in guideline-recommended heart failure medication between Dutch heart failure clinics: An analysis of the CHECK-HF registry. Neth Heart J 2020;28:334-344. https://doi.org/10.1007/s12471-020-01421-1
Seferović PM, Vardas P, Jankowska EA, Maggioni AP, Timmis A, Milinković I, et al.; in collaboration with the National Heart Failure Societies of the ESC member countries. The Heart Failure Association Atlas: Heart failure epidemiology and management statistics 2019. Eur J Heart Fail 2021;23:906-914. https://doi.org/10.1002/ejhf.2143
Metra M, Tomasoni D, Adamo M, Bayes-Genis A, Filippatos G, Abdelhamid M, et al. Worsening of chronic heart failure: Definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2023;25:776-791. https://doi.org/10.1002/ejhf.2874
Greene SJ, Bauersachs J, Brugts JJ, Ezekowitz JA, Lam CSP, Lund LH, et al. Worsening heart failure: Nomenclature, epidemiology, and future directions: JACC review topic of the week. J Am Coll Cardiol 2023;81:413-424. https://doi.org/10.1016/j.jacc.2022.11.023
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2022;79:e263-e421. https://doi.org/10.1016/j.jacc.2021.12.012
Savarese G, Hage C, Benson L, Schrage B, Thorvaldsen T, Lundberg A, et al. Eligibility for sacubitril/valsartan in heart failure across the ejection fraction spectrum: Real-world data from the Swedish Heart Failure Registry. J Intern Med 2021;289:369-384. https://doi.org/10.1111/joim.13165
Kapelios CJ, Lainscak M, Savarese G, Laroche C, Seferovic P, Ruschitzka F, et al.; Heart Failure Long-Term Registry Investigators. Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: Bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world. Eur J Heart Fail 2019;21:1383-1397. https://doi.org/10.1002/ejhf.1532
Lund LH, Savarese G, Venkateshvaran A, Benson L, Lundberg A, Donal E, et al. Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON-HF trial. ESC Heart Fail 2022;9:164-177. https://doi.org/10.1002/ehf2.13705
Thorvaldsen T, Benson L, Dahlstrom U, Edner M, Lund LH. Use of evidence-based therapy and survival in heart failure in Sweden 2003-2012. Eur J Heart Fail 2016;18:503-511. https://doi.org/10.1002/ejhf.496
Stolfo D, Lund LH, Becher PM, Orsini N, Thorvaldsen T, Benson L, et al. Use of evidence-based therapy in heart failure with reduced ejection fraction across age strata. Eur J Heart Fail 2022;24:1047-1062. https://doi.org/10.1002/ejhf.2483
Lund LH, Braunschweig F, Benson L, Ståhlberg M, Dahlström U, Linde C. Association between demographic, organizational, clinical, and socio-economic characteristics and underutilization of cardiac resynchronization therapy: Results from the Swedish Heart Failure Registry. Eur J Heart Fail 2017;19:1270-1279. https://doi.org/10.1002/ejhf.781
Kapelios CJ, Canepa M, Benson L, Hage C, Thorvaldsen T, Dahlström U, et al. Non-cardiology vs. cardiology care of patients with heart failure and reduced ejection fraction is associated with lower use of guideline-based care and higher mortality: Observations from the Swedish Heart Failure Registry. Int J Cardiol 2021;343:63-72. https://doi.org/10.1016/j.ijcard.2021.09.013
Matan D, Löfström U, Corovic Cabrera C, Eriksson B, Ekström M, Hage C, et al. Reorganization of heart failure management and improved outcome - The 4D HF project. Scand Cardiovasc J 2021;55:1-8. https://doi.org/10.1080/14017431.2020.1820075
Lund LH, Oldgren J, James S. Registry-based pragmatic trials in heart failure: Current experience and future directions. Curr Heart Fail Rep 2017;14:59-70. https://doi.org/10.1007/s11897-017-0325-0
Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al.; SOLOIST-WHF Trial Investigators. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med 2021;384:117-128. https://doi.org/10.1056/NEJMoa2030183
Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al.; EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021;385:1451-1461. https://doi.org/10.1056/NEJMoa2107038
Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al.; DELIVER Trial Committees and Investigators. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 2022;387:1089-1098. https://doi.org/10.1056/NEJMoa2206286
Crespo-Leiro MG, Metra M, Lund LH, Milicic D, Costanzo MR, Filippatos G, et al. Advanced heart failure: A position statement of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2018;20:1505-1535. https://doi.org/10.1002/ejhf.1236
Chioncel O, Parissis J, Mebazaa A, Thiele H, Desch S, Bauersachs J, et al. Epidemiology, pathophysiology and contemporary management of cardiogenic shock - A position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2020;22:1315-1341. https://doi.org/10.1002/ejhf.1922
Maack C, Eschenhagen T, Hamdani N, Heinzel FR, Lyon AR, Manstein DJ, et al. Treatments targeting inotropy. Eur Heart J 2019;40:3626-3644. https://doi.org/10.1093/eurheartj/ehy600
Lund LH. Optimal eligibility criteria for trials in heart failure with preserved ejection fraction. J Card Fail 2017;23:528-529. https://doi.org/10.1016/j.cardfail.2017.05.017
Lund LH. Complex relationships between co-morbidity, outcomes, and treatment effect in heart failure. Eur J Heart Fail 2018;20:511-513. https://doi.org/10.1002/ejhf.1107
Lund LH, Trochu JN, Meyns B, Caliskan K, Shaw S, Schmitto JD, et al. Screening for heart transplantation and left ventricular assist system: Results from the ScrEEning for advanced Heart Failure treatment (SEE-HF) study. Eur J Heart Fail 2018;20:152-160. https://doi.org/10.1002/ejhf.975
Lund LH, Hage C, Savarese G. Implementation science and potential for screening in heart failure. Eur Heart J 2022;43:413-415. https://doi.org/10.1093/eurheartj/ehab751
Aktaa S, Batra G, Cleland JGF, Coats A, Lund LH, McDonagh T, et al.; Heart Failure Association of the European Society of Cardiology. Data standards for heart failure: The European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart). Eur Heart J 2022;43:2185-2195. https://doi.org/10.1093/eurheartj/ehac151
Schroeder M, Lim YMF, Savarese G, Suzart-Woischnik K, Baudier C, Dyszynski T, et al. Sex differences in the generalizability of randomized clinical trials in heart failure with reduced ejection fraction. Eur J Heart Fail 2023;25:912-921. https://doi.org/10.1002/ejhf.2868
Stolfo D, Lund LH, Benson L, Lindberg F, Ferrannini G, Dahlström U, et al. Real-world use of sodium-glucose cotransporter 2 inhibitors in patients with heart failure and reduced ejection fraction: Data from the Swedish Heart Failure Registry. Eur J Heart Fail 2023;25:1648-1658. https://doi.org/10.1002/ejhf.2971
Canepa M, Kapelios CJ, Benson L, Savarese G, Lund LH. Temporal trends of heart failure hospitalizations in cardiology versus noncardiology wards according to ejection fraction: 16-year data from the SwedeHF registry. Circ Heart Fail 2022;15:e009462. https://doi.org/10.1161/CIRCHEARTFAILURE.121.009462